Samsung Bioepis Co., Ltd.
Quick facts
| Founded | 2012 |
|---|
Marketed products
- Lucentis (ranibizumab) · Ophthalmology
Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye. - SB5 · Immunology; Rheumatology
SB5 is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. - SB5 (Adalimumab Biosimilar) · Immunology
SB5 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
Phase 3 pipeline
- Herceptin (trastuzuamb) · Oncology
Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death. - Prolia® (Denosumab) · Osteoporosis, Bone-related disorders
Prolia works by binding to RANKL, a protein involved in the formation and activation of osteoclasts, which are cells that break down bone. - SB27 · Rheumatology
SB27 is a biosimilar to adalimumab, a TNF-alpha inhibitor. - SB8 · Oncology
SB8 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. - Soliris (eculizumab) · Immunology
Soliris works by inhibiting the complement system by blocking the action of C5.
Phase 2 pipeline
- Adalimumab PFS and Pen · Immunology
TNF-alpha inhibitor
Phase 1 pipeline
- EU Remicade
- EU sourced Enbrel
- EU sourced Herceptin®
- EU sourced Humira®
- Pen of SB5
- PFS of SB5
- SB26
- US Remicade
- US sourced Enbrel
- US sourced Herceptin®
- US sourced Humira®
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Samsung Bioepis Co., Ltd.
What are Samsung Bioepis Co., Ltd.'s marketed drugs?
Top marketed products include Lucentis (ranibizumab), SB5, SB5 (Adalimumab Biosimilar).
What is Samsung Bioepis Co., Ltd.'s pipeline?
Samsung Bioepis Co., Ltd. has 5 drugs in Phase 3, 1 in Phase 2, 11 in Phase 1. Late-stage candidates include Herceptin (trastuzuamb), Prolia® (Denosumab), SB27, SB8.
When was Samsung Bioepis Co., Ltd. founded?
Samsung Bioepis Co., Ltd. was founded in 2012.
Related
- Lucentis (ranibizumab) · Ophthalmology
- SB5 · Immunology; Rheumatology
- SB5 (Adalimumab Biosimilar) · Immunology
- Sector hub: All tracked pharma companies